uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. Chief Legal Officer Jeannette Potts reported an open-market sale of 5,237 ordinary shares at a weighted average price of about $27.67 per share. The shares were sold automatically upon RSU vesting solely to cover estimated withholding taxes, and she continues to hold 133,246 shares directly.
UniQure N.V. submitted a Form 144 notice to sell 5,295 Ordinary Shares on 06/17/2026 pursuant to a stock option exercise under a 10b5-1 plan. The proposed sale lists Citigroup Global Markets, Inc. as the broker and indicates cash proceeds.
The filing also reports two recent dispositions by Jack Kaye: 2,645 shares sold on 06/03/2026 for $79,384.35 and 1,993 shares sold on 06/11/2026 for $53,938.39.
UniQure N.V. reported Section 144 sale notices for Ordinary Shares executed on 06/17/2026 pursuant to a 10b5-1 plan. The filing lists a sale method as stock option exercise and sale for 11,685 shares with cash proceeds. The excerpt also shows prior sales by Balachandran Madhavan on 06/11/2026 (1,993 shares) and 06/15/2026 (10,000 shares).
uniQure N.V. reported that the U.S. FDA has indicated the 3-year analysis from its Phase I/II study of AMT-130 in Huntington’s disease can serve as the primary basis of a Biologics License Application for accelerated approval. Based on this feedback, the company plans to submit a BLA for AMT-130 in the third quarter of 2026, targeting patients with early manifest Huntington’s disease.
Before submission, uniQure and FDA aim to align on the design of a required confirmatory study, potentially using a concurrent standard-of-care control instead of a sham procedure. AMT-130 already holds RMAT, Breakthrough Therapy and Fast Track designations, underscoring regulatory focus on a serious disease with no approved disease-modifying therapies.
uniQure N.V. reported results from its 2026 annual meeting, where shareholders approved all proposals on the agenda. They adopted an amendment to the 2014 Share Incentive Plan to increase the number of ordinary shares reserved for equity compensation, following prior approval by the board.
Shareholders also approved amendments to the Articles of Association to reflect the Dutch large company regime, increase authorized share capital and ordinary shares, and add a U.S. federal court exclusive‑forum provision for certain disputes. All director reappointments, share issuance and repurchase authorities, auditor appointment, and advisory executive compensation votes received strong support based on the reported tallies.
uniQure N.V. director David D. Meek reported a mix of equity awards and a small share sale. He received 7,550 restricted share units under the company’s 2014 Share Incentive Plan, each representing one Ordinary Share that vests in full on the first anniversary of the grant, subject to continued service.
Meek was also granted stock options for 13,980 Ordinary Shares at an exercise price of $26.82 per share, vesting 100% after one year and expiring on June 10, 2036. In a separate transaction, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 solely to cover estimated withholding taxes upon RSU vesting, pursuant to automatic instructions, leaving him with 39,747 shares held directly.
uniQure N.V. director Robert Gut reported a mix of equity grants, option exercises, and share sales in Ordinary Shares. On June 10, 2026, he received 7,550 restricted share units at no cost and a stock option for 13,980 shares with a $26.82 exercise price expiring on June 10, 2036. He also exercised options for 2,645 shares at a $16.04 exercise price.
Across June 10–11, 2026, Gut sold 10,278 shares in open‑market transactions at weighted average prices around the mid‑$26 range, including 2,645 shares sold solely to cover estimated withholding taxes upon RSU vesting. The remaining sales were executed under a Rule 10b5‑1 trading plan adopted on July 8, 2025. After these transactions, he directly holds 32,259 Ordinary Shares.
uniQure N.V. Chief Customer & Strat Officer Kylie O’Keefe reported a tax-related share sale. On June 11, 2026, she sold 15,936 ordinary shares at a weighted average price of $27.06 per share in open-market transactions.
The footnotes state the shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and the sale was not a discretionary trade. After these transactions, she directly holds 108,864 ordinary shares.
uniQure N.V. director Jeremy P. Springhorn reported a mix of equity awards and a small share sale. On June 10, he received 7,550 restricted share units, each representing one Ordinary Share, which vest 100% on the first anniversary of grant, and 13,980 stock options with a $26.82 exercise price expiring in 2036, also vesting after one year.
On June 11, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 solely to cover estimated withholding taxes upon RSU vesting under automatic instructions, not as a discretionary trade. Following these transactions, he directly holds 43,251 Ordinary Shares.